Where Will Phoenix New Media Ltd ADR (FENG) Stock Go Next After It Is Higher By 40.93% in a Week?

The market has been high on Phoenix New Media Ltd ADR (FENG) stock recently. FENG gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Phoenix New Media Ltd ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FENG!

See Full FENG Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With FENG Stock Today?

Phoenix New Media Ltd ADR (FENG) stock is higher by 29.96% while the S&P 500 is lower by -1.71% as of 12:05 PM on Tuesday, May 2. FENG has risen $0.77 from the previous closing price of $2.57 on volume of 2,979,538 shares. Over the past year the S&P 500 is lower by -1.41% while FENG has risen 2.77%. FENG lost -$1.31 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Phoenix New Media Ltd ADR click here.

More About Phoenix New Media Ltd ADR

RXi Pharmaceuticals Corporation OTCQX:RXII is a biotechnology company focused on discovering developing and commercializing innovative therapies based on its proprietary next-generation RNAi platform. Therapeutics that use RNA interference or RNAi have great promise because of their ability to silence or down-regulate the expression of a specific gene that may be expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello RXi first RNAi product candidate RXI-109 entered into RXi first human trial in 2012. RXI-109 targets connective tissue growth factor CTGF a key regulatory of fibrosis and scar formation and is initially being developed to reduce or inhibit scar formation in the skin following surgery. Click Here to get the full Stock Report for Phoenix New Media Ltd ADR stock.